rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sherwin Sattarzadeh

Chief Operating Officer

Company insider

Files Form 4 as: Chief Operating Officer, Galecto.

In numbers

Trades disclosed
4
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
0
First trade
5 Jan 2026
Last trade
5 Jan 2026
Last filed
26 Jan 2026

Companies traded

Where they are an officer
GalectoOfficer · Biotechnology · last 5 Jan 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
5 Jan 2026filed 26 Jan 2026GalectoBiotechnologySEC FORM 4 Code A—190,376 at $0.00filing
5 Jan 2026filed 26 Jan 2026Galectooption or derivative · BiotechnologySEC FORM 4 Code A—444,209 at $0.00filing
5 Jan 2026filed 26 Jan 2026DMRA Damora Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—444,209 at $0.00filing
5 Jan 2026filed 26 Jan 2026DMRA Damora TherapeuticsBiotechnologySEC FORM 4 Code A—190,376 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Jennifer JarrettDirector, President and CEO · Director, President and CEO at Damora Therapeutics, filing Form 4 there in the last year
Andrew ChengDirector · Director at Damora Therapeutics, filing Form 4 there in the last year
Garrett WinslowGeneral Counsel · General Counsel at Galecto, filing Form 4 there in the last year
Fairmount Funds Management LLCDirector and 10% owner · Director and 10% owner at Galecto, filing Form 4 there in the last year
Julianne BrunoDirector · Director at Galecto, filing Form 4 there in the last year